Two ex-bluebird leaders launch Nvelop with $100M to tackle the biggest problem in gene editing

Andrew Dunn

Senior Biopharma Correspondent

Nvelop Therapeutics launched Tuesday with $100 million in seed funding to advance research from the gene editing pioneers David Liu and Keith Joung, as they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Two ex-bluebird leaders launch Nvelop with $100M to tackle the biggest problem in gene editing

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Are programs with compounded GLP-1s safe for your population?

Two ex-blue­bird lead­ers launch Nvel­op with $100M to tack­le the biggest prob­lem in gene edit­ing

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Two ex-bluebird leaders launch Nvelop with $100M to tackle the biggest problem in gene editing

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Are programs with compounded GLP-1s safe for your population?